37 completed, 4 unknown, 3 terminated, 2 withdrawn. 47 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 47 | Completed 37, Unknown 4, Terminated 3, Withdrawn 2, Recruiting 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Timolol: new trials by email Literature Review of Timolol trials Research Report on Timolol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia Timolol 0.5% eye drops and betamethasone valerate 0.1% cream, Betamethasone valerate 0.1% cream - Paronychia, EGFR-TKI | Phase 3 | Recruiting | Queen Mary Hospital, Hong Kong | 40 | 2024-10-09 | 2024-10-18 |
| Efficacy and Safety of Timolol for TKI Induced Paronychia Topical Timolol, Betamethasone Valerate - Paronychia | Phase 3 | Unknown | Queen Mary Hospital, Hong Kong | 40 | 2023-04-01 | 2023-12-20 |
| Combined Intravitreal Bevacizumab With Topical Timolol-Dorzolamide Eye Drops in Diabetic Macular Edema Injections of 1.25 mg of intravitreal bevacizumab with Timolol and Dorzolamide, Injections of 1.25 mg of intravitreal bevacizumab with artificial tears - Diabetic Macular Edema | Phase 2 / Phase 3 | Unknown | Shahid Beheshti University of Medical Sciences | 62 | 2021-10-06 | 2021-10-19 |
| A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL, A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mL - Open-angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Santen Pharmaceutical Co., Ltd. | 219 | 2019-01-20 | 2023-07-14 |
| Beta Adrenergic Antagonist for the Healing of Chronic DFU Timolol, Non biologically active gel - Chronic Diabetic Foot Ulcers, Diabetic Neuropathic Ulcers | Phase 3 | Completed | VA Office of Research and Development | 48 | 2018-07-24 | 2025-05-08 |
| PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM) PRO-122, Timolol eye drops, Dorzolamide-Timolol Ophthalmic - Primary Open-angle Glaucoma | Phase 3 | Terminated | Laboratorios Sophia S.A de C.V. | 51 | 2017-11-06 | 2025-03-06 |
| Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK) PRO-122, Krytantek Ofteno® - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Laboratorios Sophia S.A de C.V. | 60 | 2016-04-01 | 2019-12-09 |
| Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma trabodenoson 4.5% BID, trabodenoson 6.0% QD, trabodenoson 3.0% QD - Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT) | Phase 3 | Completed | Inotek Pharmaceuticals Corporation | 303 | 2015-09-01 | 2016-12-06 |
| Stop Retinal Ganglion Cell Dysfunction Study Latanoprost, Bimatoprost, Travoprost - Glaucoma | Phase 3 | Terminated | University of Miami | 28 | 2015-09-01 | 2025-08-26 |
| Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension Bimatoprost SR, Sham: Applicator Without Needle, Active Comparator: Timolol 0.5% - Glaucoma, Open-Angle, Ocular Hypertension | Phase 3 | Completed | Allergan | 528 | 2014-12-15 | 2021-07-28 |
| Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension Bimatoprost SR, Active Comparator: Timolol 0.5%, Sham: Applicator Without Needle - Glaucoma, Open-Angle, Ocular Hypertension | Phase 3 | Completed | Allergan | 594 | 2014-12-15 | 2020-06-11 |
| Efficacy and Safety Assessment of T2347 Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients T2347, Xalacom - Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Laboratoires Thea | 242 | 2014-12-01 | 2017-04-28 |
| Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution - Glaucoma, Ocular Hypertension | Phase 3 | Withdrawn | Allergan | 2013-07-01 | 2013-07-18 | |
| Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension BOL-303259-X, Timolol - Open-Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Bausch & Lomb Incorporated | 420 | 2013-01-31 | 2018-11-07 |
| Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension BOL-303259-X, Timolol - Open-Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Bausch & Lomb Incorporated | 420 | 2013-01-01 | 2018-11-21 |
| Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients Travoprost 0.004% PQ ophthalmic solution, Timolol, 0.5% or 0.25% ophthalmic solution, Travoprost Vehicle - Pediatric Glaucoma, Elevated IOP in Pediatric Patients | Phase 3 | Completed | Alcon Research | 184 | 2012-09-01 | 2015-07-23 |
| Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations Timolol and Tafluprost, Fixed Dose Combination of tafluprost and timolol - Ocular Hypertension, Open-angle Glaucoma | Phase 3 | Completed | Santen Oy | 401 | 2011-03-01 | 2012-06-08 |
| Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel Timolol + LCP, LCP - Melanoma | Phase 3 | Terminated | Centre Hospitalier Universitaire de Nice | 25 | 2011-02-16 | 2026-06-17 |
| Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies Timolol/ FDC/ Placebo/ Tafluprost - Ocular Hypertension, Open-angle Glaucoma | Phase 3 | Completed | Santen Oy | 600 | 2011-02-01 | 2013-03-13 |
| Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular Hypertension Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension, Brinzolamide 1% ophthalmic suspension, Timolol 0.5% ophthalmic solution - Open-Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Alcon Research | 328 | 2010-11-01 | 2014-04-10 |
Showing 20 of 47. Sign in to see all of them.
Ocular Hypertension (34) · Glaucoma, Open-Angle (29) · Glaucoma (23) · Hypertension (4) · Fibrosis (2) · Hypertension, Portal (2) · Paronychia (2) · Esophageal and Gastric Varices (1) · Gastrointestinal Hemorrhage (1) · Glaucoma, Angle-Closure (1) · Hydrophthalmos (1) · Liver Cirrhosis (1) · Liver Diseases (1) · Melanoma (1) · Varicose Veins (1)
Alcon Research (12) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (8) · Allergan (5) · Bausch & Lomb Incorporated (2) · Laboratorios Sophia S.A de C.V. (2) · Queen Mary Hospital, Hong Kong (2) · Santen Oy (2) · Centre Hospitalier Universitaire de Nice (1) · Inotek Pharmaceuticals Corporation (1) · Laboratoires Thea (1) · Merck Sharp & Dohme LLC (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Pfizer (1) · Santen Pharmaceutical Co., Ltd. (1) · Shahid Beheshti University of Medical Sciences (1)
United States (18) · United Kingdom (5) · France (4) · Germany (4) · Belgium (3) · Colombia (3) · Hong Kong (3) · Italy (3) · Singapore (3) · Spain (3) · Canada (2) · China (2) · Czechia (2) · Denmark (2) · Finland (2)
Auli Ropo, M.D. (2) · Jason Vittitow (2) · Pamela Smith, B.S. (2) · Andrew Burroughs, M.D. (1) · Cadmus C Rich, MD,MBA,CPE (1) · Clemens Vass, M.D. (1) · Eva Ruzickova, M.D. (1) · Guadalupe Garcia-Tsao, M.D. (1) · Guna Laganovska, M.D. (1) · Hannu Uusitalo, M.D., Prof. (1) · Ingeborg Stalmans, Professor (1)
PMID 19427617, PMID 29194198, PMID 35643967, PMID 36378864, PMID 16306522, PMID 17459480, PMID 18538406, PMID 19303163, PMID 19365194, PMID 20142538, PMID 20346127, PMID 21851642, PMID 25429421, PMID 25447269, PMID 25613811, PMID 26875002, PMID 27210275, PMID 27450828, PMID 2788589, PMID 29680880, PMID 32513257, PMID 34724172, PMID 38376643, PMID 41737851
2014 (2), R01DK046580 (1), R01EY014957 (1)